§ Federal grant opportunity · EPA-OW-OWOW-26-01
Fiscal Year (FY) 2026 Funding Opportunity for Indian Tribes and Intertribal Consortia for Nonpoint Source Management Grants Under Clean Water Act Section 319
Environmental Protection Agency is accepting applications for Fiscal Year (FY) 2026 Funding Opportunity for Indian Tribes and Intertribal Consortia for Nonpoint Source Management Grants Under Clean Water Act Section 319. The deadline is November 9, 2026 and the published award range is $175K.
Key facts
- Funder
- Environmental Protection Agency
- Application deadline
- November 9, 2026
- Award range
- $175K
- Eligibility
- See Section 2 of Notice of Funding Opportunity
- Geography
- United States
- Focus areas
- Environment
- Opportunity number
- EPA-OW-OWOW-26-01
Program overview
The purpose of this Notice of Funding Opportunity (NOFO) is to support eligible Tribes and intertribal consortia to implement approved Nonpoint Source (NPS) management programs developed pursuant to CWA Section 319(b)(1). The Clean Water Act (CWA) Section 319(h) authorizes the EPA to award grants to eligible Tribes and intertribal consortia to implement approved NPS management programs. This NOFO will fund implementation of best management practices (BMPs) and measures that have been outlined in Tribal NPS Management Program Plans to address NPS pollution sources that have been identified in a Tribe’s Assessment Report. Eligible applicants to this Notice of Funding Opportunity (NOFO) are federally recognized Tribes and intertribal consortia that meet the eligibility requirements described in Section 2.A.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Environmental Protection Agency.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 9, 2026, allowing time for registration and validation.
Related grant opportunities
- ROSES25: C.4 Planetary Science Enabling Facilities
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- DoW Spinal Cord Injury, Investigator-Initiated Research Award
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.